[Federal Register Volume 71, Number 246 (Friday, December 22, 2006)]
[Notices]
[Page 77066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-21886]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 07, 2006, Organichem 
Corporation, 33 Riverside Avenue, Rensselaer, New York 12144, made 
application by renewal to the Drug Enforcement Administration (DEA) as 
a bulk manufacturer of the basic classes of controlled substances 
listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Pentobarbital (2270).......................  II
Hydrocodone (9193).........................  II
Meperidine(9230)...........................  II
Dextropropoxyphene (9273)..................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers. In 
reference to drug code 7360 (Marihuana), the company plans to bulk 
manufacture cannabindiol as a synthetic intermediate. This controlled 
substance will be further synthesized to bulk manufacture a synthetic 
THC (7370). No other activity for this drug code is authorized for this 
registration.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR Sec.  1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than February 20, 2007.

    Dated:December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-21886 Filed 12-21-06; 8:45 am]
BILLING CODE 4410-09-P